Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Åä³¢ ³ú±âÀúµ¿¸Æ¿¡¼­ Protein Kinase C ±æÇ×Á¦¿Í Ca2 calmodulin¿¡ ÀÇÁ¸ÀûÀÎ Protein Kinase ±æÇ×Á¦·Î Çì¸ð±Û·Îºó¿¡ ÀÇÇÑ ¼öÃàÀÇ ¿ÏÈ­ Attenuation of Hemoglodin-Induced Constiction in the Rabbit Basilar Artery by Protein Kinase C Inhibitor and Ca2 Calmodulin-Dependent Protein Kinase Inhibitor

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1998³â 27±Ç 6È£ p.707 ~ 714
±èº´³², ÀÌÁ¶¿µ, ÇÑÀ¯Á¤,
¼Ò¼Ó »ó¼¼Á¤º¸
±èº´³² (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

ÀÌÁ¶¿µ (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç
ÇÑÀ¯Á¤ (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

Abstract

¼­ ·Ð
³úÇ÷°ü¿¬ÃàÀÌ ¾ÆÁ÷µµ ³úÁöÁÖ¸·ÇÏÃâÇ÷¿¡ ÀÇÇÑ ÀÌȯÀ²ÀÇ °¡Àå Å« ¿øÀÎÀÌ µÇ°í Àִµ¥, ÀûÇ÷
±¸°¡ ¿ëÇصǸ鼭 ³ª¿À´Â ¹°ÁúÀÌ ³úÇ÷°ü¿¬ÃàÀÇ ¹ß»ý¿¡ Áß¿äÇÑ ¹°ÁúÀ̶ó°í ¸¹Àº »ç¶÷µéÀÌ ÁÖ
ÀåÇÏ°í ÀÖÀ¸¸ç ±× Áß¿¡¼­µµ ƯÈ÷ »êÈ­ Çì¸ð±Û·ÎºóÀÌ °­·ÂÇÑ ¿¬ÃàÁ¦(spasmogen)·Î¼­ °¡Àå
Áß¿äÇÑ ÀÛ¿ëÀ» ÇÑ´Ù.
ÀÌ·¯ÇÑ ³úÇ÷°ü¿¬ÃàÀÌ Ç÷°üÀÌ¿ÏÁ¦¿¡ ÀÇÇØ Àß ¹ÝÀÀÇÏÁö ¾Ê±â ¶§¹®¿¡ ÀÌÀÇ ÇØ°áÀ» À§ÇØ ¸¹Àº
³ë·ÂÀ» ±â¿ïÀÌ°í ÀÖ´Ù ÃÖ±Ù µ¿¸Æ ÆòÈ°±ÙÀÇ ¼öÃàÀ» 2´Ü°è·Î ³ª´©¾î ¼³¸íÇÏ°í Àִµ¥, Çϳª´Â
ÀϽÃÀû ¼öÃà±â·Î óÀ½ ¼¼Æ÷³» Ä®½· Áõ°¡¿¡ µû¶ó calmodulin(CaM)¿¡ ÀÇÁ¸ÀûÀÎ myosin light
chain kinase(MLCK)ÀÇ È°¼ºÈ­¿¡ ÀÇÇÑ MLCÀÇ ÀλêÈ­(phosphorylation)¿¡ ÀÇÇØ ÀÌ·ç¾î Áø´Ù
°í ÇÏ¿´´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ¹ÝÀÀÀº ÀϽÃÀûÀÌ°í MLC ÀλêÈ­°¡ ³¡³­ ÈÄ¿¡µµ ±Ù ±äÀåµµ°¡ Áö
¼ÓÀûÀ¸·Î À¯ÁöµÇ´Â °ÍÀ¸·Î º¸¾Æ ÀÌ ÀÌ·ÐÀ¸·Î´Â ¼öÃà ¹ÝÀÀ¿¡´ëÇÑ ±âÀüÀ» ÃæºÐÈ÷ ¼³¸íÇÒ ¼ö
¾ø¾î Alisoy µî ¹× RasmussenµîÀº ´Ù¸¥ ±âÀüÀ» Á¦¾ÈÇÏ¿´´Ù. Áï ´Ù¸¥ Çϳª´Â Áö¼ÓÀû ¼öÃà±â
·Î pro-tein kinase C(PKC)¿¡ ÀÇÇØ ¼¼Æ÷Áú³» ¼öÃà ´Ü¹éÁúÀÇ ÀλêÈ­¿¡ ÀÇÇÑ´Ù°í ÇÏ¿´´Ù. ÀÌ
·¯ÇÑ ±Ù°Å¸¦ Åä´ë·Î MatsuiµîÀº PKCÀÇ È°¼ºÈ­°¡ Ç÷°ü¿¬ÃàÀÇ ¹ß»ý¿¡ Áß¿äÇÏ´Ù°í ÁÖÀåÇÏ¿´
´Ù.
µû¶ó¼­ Åä³¢ÀÇ »êÈ­ Çì¸ð±Û·Îºó¿¡ ÀÇÇÑ ³úÇ÷°ü¿¬ÃàÀÇ »ýü(in-vivo) ¸ðµ¨¿¡¼­ óÀ½À¸·Î
Áö±Ý±îÁö ¾Ë·ÁÁø PKC±æÇ×Á¦Áß °¡Àå ¼±ÅÃÀûÀÎ °ÍÀ¸·Î ¾Ë·ÁÁø Bisindolylmaleimides(BIS)ÀÇ
Ç÷°ü¿¬Ãà¿¡ ´ëÇÑ ¿µÇâ°ú, Ca2 /CaM¿¡ ÀÇÁ¸ÀûÀÎ protein kinase(CAM kinase
¥±)°¡ smooth muscle ¼öÃà¿¡ Áß¿äÇÑ MLC¸¦ ÀλêÈ­½ÃÅ°´Âµ¥, ÀÌÀÇ ¼±ÅÃÀûÀÎ ±æÇ×Á¦·Î ¾Ë·Á
Áø 1-[N,O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-N-phenylpiperazine Áï KN-62
°¡ Ç÷°ü¿¬Ãà¿¡ ¾î¶°ÇÑ ¿µÇâÀ» ÁÖ´ÂÁö ¾Ë¾Æº¸°í, ¶ÇÇÑ ÀÌ µÎ ¾àÁ¦ÀÇ Ç÷°ü ÀÌ¿Ï È¿°ú¸¦ ºñ±³
ÇØ º¸°íÀÚ ÇÏ¿´´Ù.
#ÃÊ·Ï#
According to the widely accepted concept that contraction of arteral smooth muscle is
dependent on the Ca2 / calamodulin and protein kinase C(PKC) systems.
it has been recently proposed that activation of these two systems in vascular smooth
muscle cells has a bearing on the pathogenesis of cerebral vasospasm. However, most
of the reported PKC inhibitors display a poor selectivity. in a rabbit 'vasospasm' model.
we tested the effect of a new PKC inhibitors (Bisindolylmaleimides : BIS) which has
been known for a relatively high degree of selectivity. and also investigated the possible
role of a Ca2 / calmodulin-dependent protein kinase (CAM kinase ¥±
inhibitor : KN-62). Filally, the vasodilating action of BIS was compared to KN-62.
The basilar artery was visualized using transclival exposure. and its diameter
monitored using videomicroscopy. Rabbit basilar artery was constricted in vivo by
topical application of phorbol dibutyrate. Application of phorbol dibutyrate elicated an
acute cintriction, reducing arterical diamer to 46.5% of baseline diameter. Treatment with
BIS(5¥ìM) attenuated phorbol dibutyrate-induced vasoconstriction to 96.2% of baseline.
Subsequently. applisation of oxyhemoglobin(oxy-Hb ; 10 4M) reduced
vascular diameter to 68.5% of baseline. This vasospastic response was reversed by
91.4% or 81.3% using BIS(5¥ìM) or KN-62(5¥ìM). respectively. Combined applications
of BIS and KN-62 to investigate the enhancing effect produced basilar arterial 94.9% of
baseline. These findings demonstrate that BIS is a potent PKC inhibitor. and PKC
system, rather than Ca2 /calmodulin system. appears to play a major role
in the occurrence of cerebal vasospasm. Additionally, we suggest that combination of
PKC with CAM kinase ¥± inhibitor may be more useful therepeutic agents for treating
cerebral vasospasm.

Å°¿öµå

Protein kinase C; Ca2 /calmodulin-dependent protein kinase; inhibitor; Vasospasm;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS